IGF1 and neoplasm: Clinical practice guidelines advocate a multi-component therapeutic approach which includes lowering of both serum GH and insulin-like growth factor 1 (IGF-1) levels, tumor volume reduction, and amelioration of signs, symptoms and co-morbidities [1–3].